A global action agenda for turning the tide on fatty liver disease DOI Creative Commons
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen

et al.

Hepatology, Journal Year: 2023, Volume and Issue: 79(2), P. 502 - 523

Published: Aug. 4, 2023

Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence related morbidity mortality. Focused dedicated interventions are urgently needed target prevention, treatment, care. Approach Results: We developed an aligned, prioritized action agenda for the global fatty community of practice. Following Delphi methodology over 2 rounds, large panel (R1 n = 344, R2 288) reviewed priorities using Qualtrics XM, indicating agreement 4-point Likert-scale providing written feedback. Priorities were revised between in R2, panelists also ranked within 6 domains: epidemiology, treatment care, models education awareness, patient perspectives, leadership policy. The consensus encompasses 29 priorities. In mean percentage “agree” responses was 82.4%, with all individual having at least super-majority (> 66.7% “agree”). highest-ranked included collaboration specialists primary care doctors on early diagnosis, address needs people living multiple morbidities, incorporation into relevant non-communicable strategies guidance. Conclusions: This consensus-driven multidisciplinary by providers, clinical researchers, policy experts provides path reduce improve outcomes. To implement this agenda, concerted efforts will be global, regional, national levels.

Language: Английский

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review DOI Creative Commons
Zobair M. Younossi, Pegah Golabi, James M. Paik

et al.

Hepatology, Journal Year: 2023, Volume and Issue: 77(4), P. 1335 - 1347

Published: Jan. 3, 2023

Background and Aims: NAFLD is a leading cause of liver-related morbidity mortality. We assessed the global regional prevalence, incidence, mortality using an in-depth meta-analytic approach. Approach Results: PubMed Ovid MEDLINE were searched for population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA). Meta-analysis was conducted random-effects models. Bias risk assessment Joanna Briggs Institute. Of 2585 reviewed, 92 (N=9,361,716) met eligibility criteria. Across study period (1990–2019), pooling prevalence estimates ultrasound-defined yielded overall 30.05% (95% CI: 27.88%–32.32%) 30.69% (28.4–33.09), respectively. Global increased by +50.4% 25.26% (21.59–29.33) in 1990–2006 38.00% (33.71–42.49) 2016–2019 ( p <0.001); +38.7% 25.16% (19.46–31.87) 34.59% (29.05–40.57) =0.029). The highest Latin America 44.37% (30.66%–59.00%), then Middle East North Africa (MENA) (36.53%, 28.63%–45.22%), South Asia (33.83%, 22.91%–46.79%), South-East (33.07%, 18.99%–51.03%), (31.20%, 25.86%–37.08%), (29.71%, 25.96%–33.76%), Pacific 28.02% (24.69%–31.60%), Western Europe 25.10% (20.55%–30.28%). Among cohort diagnosed without liver biopsy, pooled rate 1000 PY 12.60 (6.68–23.67) all-cause mortality; 4.20 (1.34–7.05) cardiac-specific 2.83 (0.78–4.88) extrahepatic cancer-specific 0.92 (0.00–2.21) liver-specific Conclusions: 30% increasing which requires urgent comprehensive strategies raise awareness address all aspects on local, regional, levels.

Language: Английский

Citations

1433
Principal component analysis DOI
Michael Greenacre, Patrick J. F. Groenen, Trevor Hastie

et al.

Nature Reviews Methods Primers, Journal Year: 2022, Volume and Issue: 2(1)

Published: Dec. 22, 2022

Language: Английский

Citations

564
Changing epidemiology, global trends and implications for outcomes of NAFLD DOI Creative Commons
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(3), P. 842 - 852

Published: May 10, 2023

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common globally, currently estimated to affect 38% of global population. A minority patients with NAFLD will progress cirrhosis or hepatocellular carcinoma, but total number this vast population that risk such severe outcomes is increasing. Worryingly, persons are affected by at an earlier age, suggesting they have longer time develop complications. With considerable changes in diet composition and urbanization, obesity type 2 diabetes among population, particular developing countries, proportion projected be further Yet, there large geographical discrepancies prevalence rates its inflammatory component non-alcoholic steatohepatitis (NASH). Such differences partly related differing socio-economic milieus, also genetic predisposition.This narrative review discusses recent epidemiology NASH from regional perspectives, as well special populations. We discuss consequences these can on hepatic extra-hepatic events.

Language: Английский

Citations

287
Current status and future trends of the global burden of MASLD DOI
Lei Miao, Giovanni Targher, Christopher D. Byrne

et al.

Trends in Endocrinology and Metabolism, Journal Year: 2024, Volume and Issue: 35(8), P. 697 - 707

Published: Feb. 29, 2024

Language: Английский

Citations

199
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world DOI
Linda Henry, James M. Paik, Zobair M. Younossi

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2022, Volume and Issue: 56(6), P. 942 - 956

Published: July 26, 2022

Summary Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in parallel with obesity and type 2 diabetes. Aim To review the global epidemiology NAFLD Methods We retrieved articles from PubMed using search terms NAFLD, epidemiology, prevalence, incidence, comorbidities. Results Over 250 were reviewed. In 2016, was 25%; this increased to >30% 2019. Prevalence Asia, Latin America Middle East‐North Africa (MENA) 30.8%, 34.5% 42.6%, respectively. age. Although higher men, post‐menopausal women similar. certain subpopulations, especially among obese those metabolic syndrome (MS). However, lean 11.2%. steatohepatitis (NASH) estimated between 2% 6% general population. Approximately 7% patients have advanced fibrosis; rates 21% 50% NASH. Overall mortality related 15–20 per 1000 person‐years, substantially NASH, components MS. Recent data suggest mortality/morbidity globally but awareness remains low healthcare providers. Conclusions poses a public health problem very high burden MENA America. Research needed better quantify full impact develop strategies improve risk stratification.

Language: Английский

Citations

142
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease DOI
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(12), P. 764 - 783

Published: Aug. 15, 2023

Language: Английский

Citations

96
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties DOI Open Access
Alina M. Allen, Jeffrey V. Lazarus, Zobair M. Younossi

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(1), P. 209 - 217

Published: Feb. 4, 2023

Language: Английский

Citations

86
Geographical similarity and differences in the burden and genetic predisposition of NAFLD DOI
Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gómez, Salvatore Petta

et al.

Hepatology, Journal Year: 2022, Volume and Issue: 77(4), P. 1404 - 1427

Published: Sept. 5, 2022

NAFLD has become a major public health problem for more than 2 decades with growing prevalence in parallel the epidemic of obesity and type diabetes (T2D). The disease burden differs across geographical regions ethnicities. Variations metabolic diseases, extent urban–rural divide, dietary habits, lifestyles, risk protective alleles can contribute to such differences. rise led remarkable increase number cases cirrhosis, hepatocellular carcinoma, hepatic decompensation, liver‐related mortality related NAFLD. Moreover, is associated multiple extrahepatic manifestations. Most them are factors progression liver fibrosis thus worsen prognosis All these comorbidities complications affect quality life subjects Given huge size population NAFLD, it expected that patients, healthcare systems, economy will suffer from ongoing In this review, we examine areas ethnicities, together distribution some well‐known genetic variants We also describe special populations including patients T2D, lean pediatric population, concomitant diseases. discuss outcomes, patient‐reported economic

Language: Английский

Citations

78
A global research priority agenda to advance public health responses to fatty liver disease DOI Creative Commons
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(3), P. 618 - 634

Published: June 20, 2023

An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications this are profound. This study aimed develop an aligned, prioritised research agenda for global community.

Language: Английский

Citations

71
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies DOI Open Access
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek

et al.

Pharmacological Reviews, Journal Year: 2024, Volume and Issue: 76(3), P. 454 - 499

Published: Jan. 30, 2024

Steatotic liver disease (SLD) displays a dynamic and complex phenotype. Consequently, the metabolic dysfunction-associated steatotic (MASLD)/metabolic steatohepatitis (MASH) therapeutic pipeline is expanding rapidly in multiple directions. In parallel, non-invasive tools for diagnosing monitoring responses to interventions are being studied, clinically feasible findings explored as primary outcomes interventional trials. The realization that distinct subgroups exist under umbrella of SLD should guide more precise personalized treatment recommendations facilitate advancements pharmacotherapeutics. This review summarizes recent updates pathophysiology-based nomenclature outlines both effective pharmacotherapeutics those MASLD/MASH, detailing their mode action current status phase 2 3 clinical Of extensive arsenal MASLD/MASH pipeline, several have been rejected, whereas other, mainly monotherapy options, shown only marginal benefits now tested part combination therapies, yet others still development monotherapies. Although successful drug candidate (or combinations) remains elusive, such approaches will ideally target MASH fibrosis while improving cardiometabolic risk factors. Due urgent need novel strategies potential availability safety tolerability data, repurposing existing approved drugs an appealing option. Finally, it essential highlight and, by extension, MASLD be recognized approached systemic affecting organs, with vigorous implementation interdisciplinary coordinated plans. Significance Statement SLD, including, among others, MASH, considered most prevalent chronic condition than one-fourth global population. aims provide information regarding pathophysiology, diagnosis, management line guidelines Collectively, hoped provided furthers understanding state direct implications stimulates additional research initiatives.

Language: Английский

Citations

31